semaglutide fda lawsuit Compound versions of GLP-1 drugs for weight loss halted by Novo Nordisk sues Hims &

Choose Ozempic (Semaglutide) If: You have type 2 diabetes and established cardiovascular disease semaglutide has a proven cardiovascular benefit (SUSTAIN-6 trial) You have pre-existing diabetic retinopathy requiring more gradual glucose reduction You have chronic kidney disease semaglutide has an approved kidney-protective indication Your insurance covers semaglutide but not tirzepatide Choose Mounjaro (Tirzepatide) If: Maximum weight loss is your primary goal the data consistently and significantly favours tirzepatide You have type 2 diabetes with persistently poor blood glucose control Your insurance or savings programme makes tirzepatide accessible at a similar cost You have PCOS with significant insulin resistance the dual GLP-1/GIP mechanism produces particularly meaningful improvements in HOMA-IR

Commonly reported effects include gastrointestinal symptoms such as nausea or stomach discomfort

We begin with a thorough medical evaluation to ensure that GLP injections are appropriate for you

Rybelsus (oral tablet): approved for type 2 diabetes, and cardiovascular outcome evidence continues to expand with trials like SOUL